PAA have just released the results of their Open Label Extension study and the results are impressive as follows:
OLE Study update reveals impressive Survival Data Highlights:
Compared to matched controls from the PRO-ACT Historical Database, treatment with monepantel results in a significantly ( 2=9.39, p=0.0022) longer survival of patients with MND/ALS
Treatment with monepantel significantly reduces the risk of death by 91% (HR=0.087, p=0.0154) compared to PRO-ACT matched controls Updated analysis of the rate of decline in ALSFRS-R to include the compassionate use program continued to show monepantel reduces the rate of disease progression
Enrolment on to the Open Label Extension Study is now complete with 10 of the 12 patients from the Phase 1 MEND Study rolling over
There were 4 patients that either had no change or had a slight improvement in ALSFRSR score while taking monepantel under compassionate use
What this shows is that Monopatel actually does stop the progression of Motor Nuron disease significantly so there may be something close to a cure,
PAA are moving onto the Phase 2/3 study which will determine actually how effective Monopatel is.
